Literature DB >> 9208379

Noradrenergic mechanisms in the prefrontal cortex.

D J Nutt1, M D Lalies, L A Lione, A L Hudson.   

Abstract

There is growing evidence that noradrenergic inputs to the prefrontal cortex (PFC) play an important role in regulating its function. This paper reviews the pharmacological control of noradrenaline (NA) release in this region, with particular reference to our studies using brain microdialysis, and also describes how NA levels are modulated by antidepressant and antipsychotic drugs. The suggestion that atypical antipsychotics such as clozapine and risperidone may produce clinical benefits by their ability to increase NA release is discussed. Finally, a new class of drugs, which show selectivity for imidazoline receptors is described. These compounds are shown to similarly increase extracellular NA in the PFC. Their potential utility as clinical treatments is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208379     DOI: 10.1177/026988119701100209

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  11 in total

Review 1.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

2.  Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task.

Authors:  Ee Peng Lim; Vivek Verma; Rajini Nagarajah; Gavin S Dawe
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

3.  The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.

Authors:  Svetlana Semenova; Athina Markou
Journal:  Eur Neuropsychopharmacol       Date:  2010-06-03       Impact factor: 4.600

4.  Neuroanatomical characterization of imidazoline I2 receptor agonist-induced antinociception.

Authors:  Justin N Siemian; Shushan Jia; Jian-Feng Liu; Yanan Zhang; Jun-Xu Li
Journal:  Eur J Neurosci       Date:  2018-03-23       Impact factor: 3.386

5.  Orexin A and B evoke noradrenaline release from rat cerebrocortical slices.

Authors:  K Hirota; T Kushikata; M Kudo; T Kudo; D G Lambert; A Matsuki
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Behavioural and physiological effects induced by an infusion of antisense to alpha(2D)-adrenoceptors in the rat.

Authors:  E S Robinson; D J Nutt; H C Jackson; A L Hudson
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

7.  Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: modulation by alpha2-adrenoceptors.

Authors:  K E Wortley; Z A Hughes; D J Heal; S C Stanford
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

8.  Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic.

Authors:  Paola Devoto; Giovanna Flore; Giada Vacca; Luigi Pira; Alessandra Arca; Maria Antonietta Casu; Luca Pani; Gian Luigi Gessa
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530

9.  Differential region-specific regulation of central alpha 1-adrenoceptor binding following chronic haloperidol and clozapine administration in the rat.

Authors:  Marie Cahir; Tim Mawhinney; David J King
Journal:  Psychopharmacology (Berl)       Date:  2003-10-08       Impact factor: 4.530

10.  Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site.

Authors:  Atsuko Kimura; Robin J Tyacke; James J Robinson; Stephen M Husbands; Michael C W Minchin; David J Nutt; Alan L Hudson
Journal:  Brain Res       Date:  2009-05-03       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.